Johnson & Johnson

J&J to challenge $195M talc verdicts in appeals court

J&J to challenge $195M talc verdicts in appeals court

Insisting that its talc-based products are harmless, Johnson & Johnson (J&J) has decided to challenge jury verdicts that declared the products harmful and ordered the company to compensate victims with millions of dollars.

On Oct. 27th, a California woman, who alleged that J&J’s baby powder caused her ovarian cancer, won a $67.5 million jury verdict against the company. It was the third consecutive trial defeat suffered by the company in the recent past.

News: 
Location: 

Johnson & Johnson withdraws Surgical Device due to Cancer Risk

Johnson & Johnson withdraws Surgical Device due to Cancer Risk

The world's largest seller of healthcare products Johnson & Johnson is withdrawing a surgical device from the global market, over fears that it can spread cancer in women. The device is used in hysterectomies and other uterine procedures.

The largest creator of surgical devices, J&J's Ethicon unit, is taking back the device from the market for women benefits who are going under hysterectomies, said Matthew Johnson, a company spokesman yesterday in an e-mail

Location: 
News: 

NICE Blocks J&J Prostate Cancer Drug Abiraterone

NICE Blocks J&J Prostate Cancer Drug Abiraterone

National Institute for Health and Care Excellence (NICE) has decided to block Johnson & Johnson’s prostate cancer drug. In an official communication, NICE informed that it is not worth giving the medicine to patients who have not received chemotherapy. The Institute of Cancer Research (ICR) health experts had suggested abiraterone acetate for men before they undergo chemotherapy.

Location: 
Laboratories: 

Johnson & Johnson suspends Sale of Power Morcellators for Fibroid Surgery

Sale of Power Morcellators for Fibroid Surgery suspended by Johnson & Johnson

Johnson & Johnson has suspended the sale of power morcellators after the FDA recently issued warning of higher risk of cancer due to the surgical procedure. The FDA had urged medical experts to avoid using power morcellators as there was high risk of some hidden cancer uterine sarcoma causing the spread of cancer to abdomen and pelvis.

Johnson & Johnson informed that the company has suspended the sale of devices used in fibroid surgery to avoid any risk to consumers.

Location: 
Person: 
News: 

J&J Provides Open Access to its Drug Clinical Trials to Outside Researchers

J&J Provides Open Access to its Drug Clinical Trials to Outside Researchers

Johnson & Johnson Group has joined hands with Yale University researchers, to provide open access to company's data from clinical trials. 'Yale University's Open Data Access' Project (YODA) is an agreement signed by the Yale researchers to offer drug findings of the J&J clinical trials to outside researchers.

This campaign has been led by AllTrials group, which describes this move by the J&J Company as a 'game-Changer' for pharmaceutical industry.

Location: 

Solanezumab and bapineuzumab fail in Trials for Alzheimer’s disease

Solanezumab and bapineuzumab fail in Trials for Alzheimer’s disease

Eli Lilly’s solanezumab and J&J’s bapineuzumab have failed in phase III trials on patients suffering from mild to moderate dementia. The trials have not found noticeable improvement in cognitive abilities of the study subjects.

Bapineuzumab trial was carried out of 2200 patients while 2000 patients participated in solanezumab trial. Eli Lilly announced that the company will carry out another trial of solanezumab but bapineuzumab trials have been halted.

Laboratories: 

FDA Panel Disapproves Anticoagulant Drug, Xarelto

Kemal Malik FDA Panel Disapproves for Use of Johnson & Johnson's Xarelto

On Thursday, Bayer HealthCare informed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has disapproved Johnson & Johnson's anticoagulant drug, Xarelto.

Location: 
Laboratories: 
Person: 

Johnson & Johnson and Pharmacyclics Leukemia Drug Proves Beneficial

Johnson & Johnson and Pharmacyclics Leukemia Drug Proves Beneficial

Ibrutinib, a leukemia drug developed jointly by Johnson & Johnson and Pharmacyclics Inc. has shown good results over long term use. The drug has shown encouraging data in midstage study for non-Hodgkin lymphoma. The data was presented at American Society of Hematology (ASH) meeting in New Orleans.

News: 
Location: 

Johnson & Johnson recalls Motrin from US retailers

Johnson & Johnson recalls Motrin from US retailers

Healthcare products giant Johnson & Johnson has issued anther recall of a pain reliever medicine called Motrin from stores across the US.

Location: 

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More